BioSpace News Archive

TLC announced that the first batch of patients has been dosed in Part 2 of the Phase II clinical trial for TLC590 in patients following bunionectomy surgery.

Avacta Group plc and Daewoong Pharmaceutical Co. Ltd. are pleased to announce that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Monday, January 13, 2020.

Calibre Scientific is pleased to announce that it has completed the acquisition of the NeXtal Biotechnologies line of structural biology products from Qiagen NV.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical trial evaluating CP101.

A new nationwide poll of veterinary practices confirms that new guidance proposed by the Food & Drug Administration would have a significant negative impact on their practices and their patients’ health if issued and enforced.

Immunic, Inc. announced that its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo Co., Ltd., has exercised its exclusive global option to license a group of compounds, designated by Immunic as IMU-856.

TransEnterix, Inc. announced that the Ochsner Health System has entered into an agreement to lease and utilize a Senhance® System that has been installed at the Ochsner Baptist* facility.

Largest peripheral nerve repair registry in the world generates clinical evidence of repair, safety, and outcomes data for peripheral nerve injuries

Arcturus Therapeutics, a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, announced the appointment of Steve Hughes, M.D., as Chief Development Officer, effective January 2, 2020.